Managing Genitourinary Syndrome of Menopause
Genitourinary syndrome of menopause (GSM) is one of the most common yet underrecognized consequences of menopause. Unlike vasomotor symptoms, which often improve over time, GSM is typically chronic and progressive if left untreated. An estimated 84% of postmenopausal women develop GSM within six years of menopause, yet many never receive appropriate assessment or treatment. A substantial proportion report that their clinician has never initiated a conversation about vaginal, sexual, or urinary symptoms.
.jpg)
Learning Outcomes
What you'll learn
- Describe the hormonal and tissue changes that contribute to genitourinary syndrome of menopause, including the roles of estrogen and androgen deficiency.
- Explain the epidemiology and chronic progressive nature of GSM.
- Identify common genital, sexual, and urinary presentations of GSM in postmenopausal patients.
- Apply brief, practical screening questions during routine clinical encounters.
- Differentiate GSM from other vulvovaginal and urinary conditions.
- Conduct a focused assessment including relevant history and physical examination.
- Select individualized, evidence-based treatment options based on symptom severity, patient preferences, and contraindications.
- Counsel patients regarding local estrogen therapy, nonhormonal therapies, and other emerging treatment options.
- Use shared decision-making strategies to improve treatment adherence and patient confidence.
- Develop long-term follow-up plans that address symptom monitoring, quality of life, and recurrence prevention.
Stay updated with our
Learning Outcomes
What you'll learn
- Describe the hormonal and tissue changes that contribute to genitourinary syndrome of menopause, including the roles of estrogen and androgen deficiency.
- Explain the epidemiology and chronic progressive nature of GSM.
- Identify common genital, sexual, and urinary presentations of GSM in postmenopausal patients.
- Apply brief, practical screening questions during routine clinical encounters.
- Differentiate GSM from other vulvovaginal and urinary conditions.
- Conduct a focused assessment including relevant history and physical examination.
- Select individualized, evidence-based treatment options based on symptom severity, patient preferences, and contraindications.
- Counsel patients regarding local estrogen therapy, nonhormonal therapies, and other emerging treatment options.
- Use shared decision-making strategies to improve treatment adherence and patient confidence.
- Develop long-term follow-up plans that address symptom monitoring, quality of life, and recurrence prevention.
Stay updated with our
Training Overview
- Understanding Genitourinary Syndrome of Menopause
- Recognizing Clinical Presentations and Screening
- Assessment and Diagnosis in Clinical Practice
- Evidence-Based Treatment Options
- Shared Decision-Making, Counselling, and Adherence
- Complex Cases, Multidisciplinary Care, and Long-Term Management
- Summary
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
Top reviews
No reviews yet.
You May Also Like
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
Take Your
Learning Anywhere
Stay on top of your learning with the Care Learning app.
Are you a qualified
Trainer or Instructor?
Join Care Learning as a trainer and deliver high-quality courses to learners across healthcare and workplace training.
Refer a Friend &
Earn Rewards.
Invite healthcare professionals to join Care Learning and get rewarded when your referral successfully joins.
Frequently asked questions
GSM is a collection of genital, sexual, and urinary symptoms caused by the decline in estrogen and androgen activity after menopause. It can affect the vagina, vulva, urethra, bladder, and sexual function.
Yes. Vaginal dryness is only one component of GSM. The syndrome may also include burning, irritation, dyspareunia, urinary urgency, frequency, dysuria, and recurrent urinary tract infections.
Unlike hot flashes, GSM is usually chronic and progressive if left untreated. Symptoms often persist or worsen over time because the underlying hormonal deficiency continues.
No. Low-dose vaginal estrogen is applied directly to vaginal tissues and generally results in much lower systemic absorption than oral or transdermal menopausal hormone therapy.
Yes, but management should be individualized. Nonhormonal therapies are often considered first, and decisions about local hormonal therapy should involve careful risk assessment and, when appropriate, collaboration with the oncology team.
Lubricants may provide immediate relief during intercourse, while local vaginal estrogen often begins improving symptoms within weeks, with maximal tissue restoration occurring over several months.